CO6561823A2 - Composiciones de pirroloquinolinil -pirrolidin -2.5-diona purificada y métodos de prepararlas y emplearlas - Google Patents

Composiciones de pirroloquinolinil -pirrolidin -2.5-diona purificada y métodos de prepararlas y emplearlas

Info

Publication number
CO6561823A2
CO6561823A2 CO12122679A CO12122679A CO6561823A2 CO 6561823 A2 CO6561823 A2 CO 6561823A2 CO 12122679 A CO12122679 A CO 12122679A CO 12122679 A CO12122679 A CO 12122679A CO 6561823 A2 CO6561823 A2 CO 6561823A2
Authority
CO
Colombia
Prior art keywords
quinolin
pyrrolo
pyrrolidin
dione
dihydro
Prior art date
Application number
CO12122679A
Other languages
English (en)
Inventor
David Reed
Neil R Barnes
Jhon F Kane
Christopher Lee
Jian Xie Chen
Martin P Redmon
Original Assignee
Arqule Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arqule Inc filed Critical Arqule Inc
Publication of CO6561823A2 publication Critical patent/CO6561823A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a un polimorfo de forma 1 y forma 2 de (-)-trans-3- (5,6-dihidro-4H-pirrolo [3,2,1-ij] quinolin-1-iI)-4-(1H-indol-3-ij) pirrolidin-2,5-diona. La presente invención se refiere asimismo a compuestos de (-)-trans-3-(5,6- dihidro-4H-pirrolo [3,2,1-ij] quinolin-1-il)-4-(1H-indol-3-il) pirrolidin-2,5-diona que tienen una pureza quiral de más de 99%, y a métodos de preparación de estos compuestos. La presente invención se refiere igualmente a composiciones farmacéuticas que contienen estos compuestos de (-)-trans-3-(5,6-dihidro-4H- pirrolo [3,2,1-ij] quinolin-1-il)-4-(1H-indol-3-iI) pirrolidin-2,5-diona. La presente invención proporciona métodos de tratar un trastorno proliferativo celular, tal como cáncer, administrando a un sujeto necesitado de ello una cantidad terapéuticamente efectiva de una composición que contiene (-)-trans-3-(5,6-dihidro-4H-pirrolo [3,2,1-ij] quinolin-1-il)-4-(1H-indol-3-il) pirrolidin-2,5-diona, que tiene una pureza quiral de más de 99% o un polimorfo de forma 1 y forma 2 de (-)- trans-3-(5,6-dihidro-4H-pirrolo [3,2,1-ij] quinolin-1-il)-4-(1H-indol-3-iI) pirrolidin-2,5- diona.
CO12122679A 2009-12-23 2012-07-23 Composiciones de pirroloquinolinil -pirrolidin -2.5-diona purificada y métodos de prepararlas y emplearlas CO6561823A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28956309P 2009-12-23 2009-12-23

Publications (1)

Publication Number Publication Date
CO6561823A2 true CO6561823A2 (es) 2012-11-15

Family

ID=44188284

Family Applications (1)

Application Number Title Priority Date Filing Date
CO12122679A CO6561823A2 (es) 2009-12-23 2012-07-23 Composiciones de pirroloquinolinil -pirrolidin -2.5-diona purificada y métodos de prepararlas y emplearlas

Country Status (19)

Country Link
US (3) US8552192B2 (es)
EP (2) EP3081567A3 (es)
JP (2) JP2013515737A (es)
KR (2) KR101669707B1 (es)
CN (2) CN104910159A (es)
AU (2) AU2010336533B9 (es)
BR (1) BR112012015656A2 (es)
CA (1) CA2785503A1 (es)
CO (1) CO6561823A2 (es)
HK (1) HK1215025A1 (es)
MX (1) MX2012007259A (es)
MY (1) MY156701A (es)
NZ (2) NZ628087A (es)
PH (1) PH12014500310A1 (es)
RU (1) RU2556205C2 (es)
SG (1) SG181927A1 (es)
TW (3) TWI506026B (es)
WO (1) WO2011079142A2 (es)
ZA (1) ZA201204759B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101941970B (zh) * 2005-02-09 2013-08-21 艾科优公司 用于治疗癌症的meleimide衍生物、药物组合物以及方法
CA2785503A1 (en) * 2009-12-23 2011-06-30 Arqule, Inc. Purified pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same
AU2012278831A1 (en) * 2011-07-07 2014-01-16 Arqule, Inc Pyrroloquinolinyl-pyrrolidine-2,5-dione formulations and methods for preparing and using same
US9000005B2 (en) 2012-04-23 2015-04-07 Arqule, Inc. Highly pure pyrroloquinolinyl-pyrrole-2,5-dione and pyrroloquinolinyl-pyrrolidine-2,5-dione and methods of preparing same
WO2015008221A1 (en) * 2013-07-16 2015-01-22 Dr. Reddy’S Laboratories Limited Novel crystalline forms of pemetrexed tromethamine salts
KR102700883B1 (ko) * 2017-08-11 2024-09-02 액투에이트 테라퓨틱스 인크. 3-(5-플루오로벤조푸란-3-일)-4-(5-메틸-5H-[1,3]디옥솔로[4,5-f]인돌-7-일)피롤-2,5-디온의 고체 형태
CN110806454A (zh) * 2018-08-06 2020-02-18 江苏正大清江制药有限公司 一种盐酸吉西他滨中手性异构体的检测方法
CN114364798A (zh) 2019-03-21 2022-04-15 欧恩科斯欧公司 用于治疗癌症的Dbait分子与激酶抑制剂的组合
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
EP4319740A1 (en) * 2021-04-07 2024-02-14 Urica Therapeutics, Inc. Urat1 inhibitor, pharmaceutical compositions and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
DE4128015A1 (de) * 1991-08-23 1993-02-25 Kali Chemie Pharma Gmbh 1,7-anellierte 2-(piperazinoalkyl)indol-derivate sowie verfahren und zwischenprodukte zu ihrer herstellung und diese verbindugnen enthaltende arzneimittel
US5760237A (en) * 1995-08-25 1998-06-02 California Institute Of Technology Synthesis of l-azatyrosine using pseudoephedrine as a chiral auxiliary
US6867198B2 (en) * 1999-12-16 2005-03-15 Eli Lilly And Company Agents and methods for the treatment of proliferative diseases
WO2004013069A1 (en) * 2002-07-31 2004-02-12 Firmenich Sa A process for the optical resolution of a precursor of sclareolide
US20060058532A1 (en) * 2004-09-10 2006-03-16 Warren Chew Process for the scalable synthesis of 1,3,4,9-tetrahydropyrano[3,4-b]-indole derivatives
CN101941970B (zh) * 2005-02-09 2013-08-21 艾科优公司 用于治疗癌症的meleimide衍生物、药物组合物以及方法
US20070185346A1 (en) * 2006-02-03 2007-08-09 Vaidya Niteen A Kit for automated resolving agent selection and method thereof
WO2009002807A2 (en) * 2007-06-22 2008-12-31 Arqule, Inc. Indolyl pyrrolidines for the treatment of cancer
EP2170870B1 (en) 2007-06-22 2014-03-05 ArQule, Inc. Pyrrolidinone, pyrrolidine-2, 5-dione, pyrrolidine and thiosuccinimide derivatives, compositions and methods for treatment of cancer
CA2785503A1 (en) * 2009-12-23 2011-06-30 Arqule, Inc. Purified pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same
US9000005B2 (en) * 2012-04-23 2015-04-07 Arqule, Inc. Highly pure pyrroloquinolinyl-pyrrole-2,5-dione and pyrroloquinolinyl-pyrrolidine-2,5-dione and methods of preparing same

Also Published As

Publication number Publication date
WO2011079142A3 (en) 2011-11-24
ZA201204759B (en) 2014-03-26
CN102834097A (zh) 2012-12-19
WO2011079142A2 (en) 2011-06-30
EP3081567A2 (en) 2016-10-19
EP2515904A4 (en) 2013-07-03
AU2010336533A1 (en) 2012-07-12
US20110160242A1 (en) 2011-06-30
NZ628087A (en) 2016-02-26
TW201141865A (en) 2011-12-01
PH12014500310A1 (en) 2015-09-28
KR101669707B1 (ko) 2016-10-27
SG181927A1 (en) 2012-07-30
CA2785503A1 (en) 2011-06-30
TWI506026B (zh) 2015-11-01
AU2015243015A1 (en) 2015-11-05
TWI557125B (zh) 2016-11-11
RU2012131344A (ru) 2014-01-27
US20140031551A1 (en) 2014-01-30
HK1215025A1 (zh) 2016-08-12
MX2012007259A (es) 2015-05-15
US8871933B2 (en) 2014-10-28
EP3081567A3 (en) 2016-11-16
US20160024076A1 (en) 2016-01-28
CN102834097B (zh) 2015-06-17
JP2016041712A (ja) 2016-03-31
AU2010336533B9 (en) 2015-10-08
AU2015243015B2 (en) 2017-02-02
MY156701A (en) 2016-03-15
EP2515904A2 (en) 2012-10-31
BR112012015656A2 (pt) 2016-05-10
RU2556205C2 (ru) 2015-07-10
US8552192B2 (en) 2013-10-08
TW201542546A (zh) 2015-11-16
US9499540B2 (en) 2016-11-22
TW201643163A (zh) 2016-12-16
CN104910159A (zh) 2015-09-16
JP2013515737A (ja) 2013-05-09
NZ600800A (en) 2014-10-31
AU2010336533B2 (en) 2015-09-10
KR20160121602A (ko) 2016-10-19
KR20120113760A (ko) 2012-10-15

Similar Documents

Publication Publication Date Title
CO6561823A2 (es) Composiciones de pirroloquinolinil -pirrolidin -2.5-diona purificada y métodos de prepararlas y emplearlas
MX2007009649A (es) Derivados de meleimida, composiciones farmaceuticas y metodos para el tratamiento del cancer.
MY157124A (en) Substituted imidazopyridinyl-aminopyridine compounds
MX2011006959A (es) Compuestos substituidos de 5,6-dihidro-6-fenilbenzo [f] isoquinolina-2-amina.
CL2011000504A1 (es) Compuestos derivados de piridin-4-il-tiazol-2il-amida 2-amida-pirrolidin-1,2-dicarboxilico, inhibidores de quinasa de fosfatidil-inositol-3; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de un medicamento para el tratamiento del cancer.
MX2009013815A (es) Compuestos de quinazolinona y metodos de uso para los mismos.
NZ600430A (en) Spiro-oxindole mdm2 antagonists
MX2012000711A (es) Inhibidores de pirrolopirazina de cinasas.
WO2011082266A3 (en) Substituted heterocyclic compounds
EA201200519A1 (ru) Стабилизированные жидкие и лиофилизированные композиции adamts13
WO2011082273A3 (en) Substituted pyrrolo-aminopyrimidine compounds
EA201071320A1 (ru) Активаторы глюкокиназы
MX2012000709A (es) Inhibidores de pirrolopiridina de cinasas.
MX2010008531A (es) Derivados de bifenilo conformacionalmente restringido para uso como inhibidores del virus de la hepatitis c.
WO2011082267A3 (en) Substituted triazolo-pyrazine compounds
WO2009117676A3 (en) Novel piperidine derivatives as inhibitors of stearoyl-coa desaturase
UA98804C2 (ru) Катехоламиновые производные и фармацевтическая композиция на их основе
NZ718514A (en) Compounds, compositions and methods useful for cholesterol mobilisation
EA201001196A1 (ru) Соединения 4-пиридинона и их применение для лечения рака
WO2011082268A3 (en) Substituted naphthalenyl-pyrimidine compounds
WO2009002807A3 (en) Indolyl pyrrolidines for the treatment of cancer
ATE538105T1 (de) Substituierte tetrazolverbindungen und ihre verwendung
WO2011082271A3 (en) Substituted triazolo-pyrimidine compounds
PH12015501980A1 (en) Pyrroloquinolinyl-pyrrolidine-2,5-dione formulations and methods for preparing and using same
NZ629475A (en) Pharmaceutical composition comprising benzyl alcohol for the treatment of migraines

Legal Events

Date Code Title Description
FG Application granted